Alternatives to KaliVir Immunotherapeutics, Inc.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

Developing novel immunotherapies and diagnostics for cancer.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A biotechnology company developing genetic therapies for rare disorders.

Developing gene editing therapies to lower cholesterol.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Pioneering vision restoration therapies for severe retinal degenerations.

Developing ultrasound-mediated nonviral genetic medicines.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Developing first-in-class oral therapy for BK polyomavirus infections.

A biotechnology company focused on oncology drug discovery.

Immunotherapy company targeting oncology and autoimmune diseases.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Developing novel male contraceptives.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Scalable, one-time curative in-vivo gene editing therapies.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

South Korean biopharmaceutical company developing novel biologics for cancer and rare diseases.

Develops and distributes bioreactor technology for stem cell cultivation.

Developing a new histotripsy therapeutic platform for cancer treatment.

Platform designed to cut cell and gene therapy production costs.

A biopharmaceutical company focused on drug discovery and development.

Advancing targeted alpha therapies.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

AI-enabled technology for cell biology research and biopharma development.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.